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Abstract
Background: c-FLIP can be considered as a tumor-progression factor in regard to its anti-
apoptotic functions. In the present study, we intended to investigate the expression of c-FLIP in
human HCC tissues, and its relation with drug-induced cell apoptosis through the specific inhibition
of c-FLIP expression by siRNA in 7721 cells.
Methods: c-FLIP expression was quantified immunohistochemically in HCC tissues(eighty-six
cases), and corresponding noncancerous tissues (fifty-seven cases). Patients with HCC were
followed up for cancer recurrence. Then, the c-FLIP gene was silenced with specific siRNA in 7721
HCC cells. c-FLIP expression was detected by RT-PCR, Western Blot and immunocytochemical
staining. The cellular viability and cell apoptosis were assayed in vitro with cells treated with
doxorubicin.
Results: Positive immunostaining was detected for c-FLIP in 83.72% (72/86) human HCC tissues,
14.81% (4/27) hepatic cirrhosis, 11.11% (2/18) hepatic hemangioma tissues, and absent in normal
hepatic tissues. The overexpression(more than 50%) of c-FLIP in HCC adversely affected the
recurrence-free survival. Through c-FLIP gene silencing with siRNA, the expressions of c-FLIP
mRNA and protein were remarkably down-regulated in 7721 HCC cells. And doxorubicin showed
apparent inhibition on cell proliferations, and induced more apoptosis.
Conclusion: These results indicate that c-FLIP is frequently expressed in human HCCs, and its
overexpression implied a lesser probability of recurrence-free survival. The specific silencing of c-
FLIP gene can apparently up-regulate drug-induced HCC cell apoptosis, and may have therapeutic
potential for the treatment of human HCC.
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Background
Human HCC (hepatocellular carcinomas) is the common
hepatic highly malignant tumor. Most patients, especially
in China, present at diagnosis with a high stage. The etio-
pathogenisis and developments of HCC are not well
known. Deregulation of cell proliferation and cell apopto-
sis underlies neoplastic initiation and development,
which involves multiple gene alterations, and is regulated
by complicated signal transduction pathways. It has
become clear that deregulated apoptosis plays a pivotal
role in tumorigenesis, malignancy and metastatic poten-
tial [1].
Accumulating evidence suggests that multiple intrinsic
and extrinsic signaling molecules contribute to the resist-
ance to death ligands- and chemotherapeutics-induced
apoptosis in cancer cells. c-FLIP(cellular FLICE-inhibitory
protein) is a novel member of IAP(inhibitor of apoptosis
protein) family, which inhibits the apoptosis signaling
mediated by the death receptors Fas, DR4, and DR5[2,3].
c-FLIP plays a pivotal role in modulating the induction of
apoptosis in variant cancer cells [4-6]. Down-regulating c-
FLIP expression confers sensitivity to TRAIL- and Fas-
induced apoptosis.
c-FLIP has homology to caspase-8 and caspase-10, but
lacks their protease activity due to the absence of key NH2
acid residues at the active site[7]. c-FLIP belongs to the
potential negative regulators of the DR(death receptor)
pathway by interfering with caspase-8 activation. Two
splicing variants of c-FLIP, 55 kDa c-FLIPL(long form) and
25 kDa c-FLIPS(short form), have the capacity to block
DR-mediated apoptosis. c-FLIPL and c-FLIPS have been
described to be recruited to the DISC(death-inducing sig-
naling complex) and prevent caspase-8 activation in
slightly different ways. Although the precise physiological
role of c-FLIP is still debated, it is generally accepted that
c-FLIPS interferes with the initial cleavage between the p20
and the p10 subunits of caspase-8, while c-FLIPL blocks
the final cleavage step between the prodomain and the
p20 subunit of the p43/41 intermediate unit. In contrast
to c-FLIPS, c-FLIPL can interact with both FADD and cas-
pase-8, and it has the more potent inhibitory activity and
prevents caspase-8 activation by acting as a substrate trap
[8-10].
In addition, c-FLIP is a target for the major survival path-
ways involved in carcinogenesis, namely the NF-κB, Akt/
PKB and MAPK pathways [11]. Moreover, c-FLIP conveys
independent prognostic information in the presence of
classical prognosticators [12].
RNA interference (RNAi) represents a phenomenon of
double-stranded RNA (dsRNA)-mediated post-transcrip-
tional gene silencing (PTGS). RNAi can highly induce spe-
cific target gene silencing in mammalian cells using small
interfering RNA (siRNA) [13]. It has been shown that
down-regulation of c-FLIPL in many cells by siRNA sensi-
tizes the cells to ligands- and chemotherapeutics-induced
apoptosis [14].
In this study, the expression of c-FLIP in human HCC tis-
sues and corresponding noncancerous tissues was ana-
lyzed by immunohistochemical staining. And then, the
plasmids, which could encode siRNA against c-FLIP, were
constructed and transfected into 7721 cells, a typical
human HCC cell line, to inhibit the c-FLIP expression for
the further study on its biological activity.
Methods
Patients and samples
Eighty-six patients with HCC presenting at Tangdu and
Xijing Hospital of FMMU between 1999 and 2006, for
whom sufficient paraffin embedded tissue was available,
were enrolled in the present investigation. All the patients
were not given the adjuvant radio- and/or chemo-therapy
before the resection. Of the patients, seventy were male
and sixteen were female with median age 65 years (range
31 to 76). The mean size of tumor was 5.5 ± 2.1 cm (mean
± SD) in diameter with a range from 2.5 to 11.0 cm(For
the patient with multiple focus, the dimension of the larg-
est tumor was recorded). Tumor staging was in accordance
to the AJCC staging system. 27 cases of hepatic cirrhosis,
eighteen cases of hepatic hemangiomas, and twelve cases
of normal hepatic tissues were used as the control.
All tissues were scored by two pathologists blinded to dis-
ease status. Grading of HCC was based on Edmondson
methods [15]. Histopathologic findings of eighty-six HCC
samples were divided into four grades according to
Edmondson standard, including 18 Grade I, 25 Grade II,
21 Grade III, 22 Grade IV. By the time this study was
undertaken, ten patients with HCC had been lost to fol-
low-up or died without known tumor recurrence, and
seven patients were excluded who were given post-opera-
tive chemotherapy. During the follow-up period, the
recurrence-free survival time for the remaining sixty-nine
patients was 15.5 months (range 5 to 53 months).
Immunohistochemical analysis of tissue c-FLIP expression
Sections (4 μm) were deparaffinized, rehydrated,
immersed in 3% H2O2 for 10 min and microwaved at 750
W in citrate buffer (pH 6.0) for 15 min. Tissue sections
were then blocked for 20 min with normal rabbit serum
and incubated overnight at 4°C with rabbit anti-human c-
FLIP polyclonal antibodies, diluted 1:200(Abcan, UK).
Incubation with PBS instead of the primary antibody
served as a negative control. After washing twice with PBS
for 2 min each, immunostaining was performed using the
standard S-P technique (Beijing Zhongshan Bio., China)Journal of Experimental & Clinical Cancer Research 2009, 28:24 http://www.jeccr.com/content/28/1/24
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and visualized with diaminobenzidine tetrahydrochlo-
ride solution.
Staining was assessed blindly by one observer. A mini-
mum of five randomly selected fields (200×) were exam-
ined, with a mean of 1500 cells counted throughout the
whole section. The labeling index was defined as the per-
centage of neoplastic cells with clear cytoplasmic immu-
noreactivity of the total number of neoplastic cells
counted. The threshold for c-FLIP positivity was 10%. The
intensity of staining was scored as 0: achromatic, 1: light
yellow, 2: yellow, 3: brown.
Construction of RNAi vectors
According the sequence of the c-FLIP mRNA, the siRNA
oligonucleotides were designed and synthesized to the
targeted RNAi regions at 526~544, 1164~1182,
1305~1323 nt. Bgl II and Hind III sites were respectively
generated at the 5' and 3' ends of the templates (as shown
below). si-526:
5'-CCCGGAGCAGGGACAAGTTACATTCAAGAGATG-
TAACTTGTCCCTGCTCCTTTTTGGAAA-3' (Forward);
5'-TTTCCAAAAAGGAGCAGGGACAAGTTACATCTCTT-
GAATGTAACTTGTCCCTGCTCCGGG-3' (Back).
si-1164:
5'-CCCGCGAGGGCTGTGCACAGTTTTCAAGAGAAACT-
GTGCACAGCCCTCGCTTTTTGGAAA-3' (Forward);
5'-TTTCCAAAAAGCGAGGGCTGTGCACAGTTTCTCTT-
GAAAACTGTGCACAGCCCTCGCGGG-3' (Back).
si-1305:
5'-CCCACGCCCACTCCTGGATCTTTTCAAGAGAAA-
GATCCAGGAGTGGGCGTTTTTTGGAAA-3' (Forward);
5'-TTTCCAAAAAACGCCCACTCCTGGATCTTTCTCTT-
GAAAAGATCCAGGAGTGGGCGTGGG-3' (Back).
These above siRNA-encoding complementary single-
stranded oligonucleotides were hybridized to give Bgl II-
and Hind III-compatible overhangs, and then ligated into
pSuper (linked overnight at 16°C). After E. Coli, DH5α,
transfected by the recombinant vectors, the positive
clones were selected. With positive plasmids, the
sequences were checked by sequencing a PCR-amplified
region containing the oligonucleotides. The recombinant
plasmids were named as pSuper-Si1, pSuper-Si2, pSuper-
Si3 and pSuper-Neg(no target segment inserted), respec-
tively.
siRNA transfections
HCC cell line, 7721, showed stronger staining intensity
(results not shown), and was used as the target cell for the
following study. 7721 cells were cultured in
RPMI1640(Invitrogen, USA) containing 10% fetal bovine
serum(FBS), and maintained in a humidified 37°C incu-
bator with 5% CO2 by routine passage every 3 days or as
needed.
Plasmids were transfected into cells according to the man-
ufacturer's protocol of LipofectamineTM 2000 (Invitro-
gen, USA). In brief, 24 hr prior to transfection, cells were
seeded without antibiotics in 6-well plate at 3 × 105 cells/
well, corresponding to a density of 80% at the time of
transfection. 4 μg plasmids and 8 μL LipofectamineTM
2000 were mixed respectively with RPMI1640 without
FBS. These reagents were combined and incubated for 20
min before adding the cells in the mixed liquor. Cells were
incubated at 37°C for 8 hr, then fresh RPMI1640 with
10% FBS was added. After another 48 hr cultivation, 400
μg/mL G418 (Promega, USA) was added in. When the cell
clones formed after 14 days' growth, cells were screened
out to be kept on cultivating. At last, the stable transfec-
tion 7721 cell clones were collected and given extended
culture.
RNA preparation and semi-quantitative real-time PCR
Total cellular RNA was extracted from 1 × 106 cells using
TRIzol reagent (Invitrogen, USA). The first strand cDNA
was prepared using the Superscript Amplification System
kit (Promega, USA) according to the manufacturer's
instructions. For PCR, the primer sequences and expected
product sizes were as follows: c-FLIP (512 bp), Forward:
5'-ATGTCTGCTGAAGTCAT CC-3', Back: 5'-ATCCTCAC-
CAATCTCCTGCC-3';  β-actin (475 bp), Forward: 5'-
TGACGGGGTCACCCACACTGTGCC-3', Back: 5'-
CTGCATCCTGTCGGCAATGCCAG-3. Amplification was
performed for 25 cycles (15 s denaturing at 95°C, 20 s
annealing at 55°C, and 20 s extension at 72°C) in a PER-
KIN ELMER Thermal Cycler PE2400.
The PCR products were analyzed on 2% agarose gels and
visualized by ethidium bromide staining. Quantitation of
expression levels was achieved after adjustment for the
expression levels of the housekeeping gene β-actin by den-
sitometry (Bio-Rad, USA). The relative level of expression
was then represented as the ratio of c-FLIP/β-actin.
Western Blot Analysis
The transfected 7721 cells were incubated for 30 min at
4°C in lysis buffer [16]. Lysates were cleared at 10,000 × g
for 10 min at 4°C. Cell lysates were washed three times in
cold lysis buffer. 100 μg of total protein was loaded on
SDS-polyacrylamide gels, separated by electrophoresis,
and transferred to nitrocellulose membranes (Millipore,Journal of Experimental & Clinical Cancer Research 2009, 28:24 http://www.jeccr.com/content/28/1/24
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USA) using standard procedures. The blots were stripped.
Blocking of membranes and incubation with the primary
(anti-c-FLIP multiclonal Abs) and appropriate secondary
Abs were performed. Bands were visualized with an ECL
detection kit (Amersham Biosciences, USA).
Immunocytochemical procedure
Cells were fixed in situ in paraformaldehyde (4% in PBS),
and smeared onto slides precoated with 0.01% poly-L-
lysine and air dried for 48 hr. Slides were washed in PBS
and put into 3% H2O2 for 15 min to remove endogenous
peroxidase activity. Slides were incubated overnight at
4°C with rabbit anti-human c-FLIP polyclonal antibodies.
Incubation with PBS instead of the primary antibody
served as a negative control. After washing twice with PBS
for 2 min each, immunostaining was performed using the
standard S-P technique and visualized with diaminoben-
zidine tetrahydrochloride solution.
Cell viability assays
For cell viability determination, 2 × 104 cell/well cell sus-
pension was plated in 96-well microplates. After treated
with doxorubicin for 0–8 days, the number of cells per
well is obtained by using counting chamber.
Determination of apoptosis by TUNEL
Cells were treated with the indicated doses of doxorubicin
for 48 hr, and then carefully harvested by centrifugation
and reattached to gelatin-covered glass slides before labe-
ling. In brief, cells (5 × 107/mL) were fixed in 4% formal-
dehyde in PBS for 25 min at 4°C. Each glass slide was
added 50–100 μL of cell suspension. After air-dry slides at
room temperature for 5 min, slides were then washed
with PBS for two times. The slides were put into 2% H2O2
for 5 minutes to remove endogenous peroxidase activity.
After removing excess liquid carefully, 50 μL of incubation
buffer (45 μL equilibration buffer, 5 μL nucleotide mix
containing fluorescein-12-dUTP, and 1 μL terminal deox-
ynucleotidyl transferase enzyme) were added to each sam-
ple. For negative controls: Prepare a control incubation
buffer without TdT Enzyme by combining 45 μL of Equi-
libration Buffer, 5 μL of Nucleotide Mix and 1 μL of auto-
claved, deionized water. They were covered with
chambered coverslip caps and placed in an incubator
under a humidified atmosphere at 37°C for 60 min.
Slides were then dipped in stop solution, and incubated
30 min at 37°C. After being washed with PBS at room
temperature, the slides were observed under a fluores-
cence microscope. Apoptosis was indicated by the pres-
ence of green or yellow-green fluorescence within the
nucleus of cells as confirmation of fluorescein-12-dUTP
incorporation at 3'-OH ends of fragmented DNA.
Statistical analysis
Differences in positive immunostaining rates and expres-
sion levels were analyzed by Chi-square test, and compar-
ison of survival curves by Mantel-Cox test, with the
software GraphPad Prism 5. The significance was set at P
< 0.05.
Results
Expression of c-FLIP in human HCC tissues
In human HCC tissues, the positive staining showed yel-
low or brown coloration in the cytoplasm and/or plasma
membranes (Figure. 1). Positive human HCC samples dis-
played stronger staining intensity, compared with the
other hepatic samples. Immunoreactivity (defined as
expression in 10% or more of neoplastic cells) was
detected for c-FLIP in 83.72%(72/86) HCC, 14.81%(4/
27) hepatic cirrhosis, 11.11%(2/18) hepatic hemangioma
samples, respectively. No immunostaining was found in
normal hepatic tissues.
The positive rate in human HCC tissues was related to
HCC grade. The rate of c-FLIP positive expression
increased with Edmondson standard. The positive expres-
sion of c-FLIP displayed in 13/18 (72.22%) samples of
Grade I HCC, 20/25 (80.00%) of Grade II, 18/21
(85.71%) of Grade III, and 21/22(95.45%) of Grade IV
class (P < 0.05). But no correlation was found between the
expression of c-FLIP and the tumor stage and size.
In univariate analysis, c-FLIP expression was not associ-
ated with HCC patient survival (P = 0.204). But c-FLIP
overexpression (more than 50%, P = 0.036) implied a
lesser probability of survival (Figure. 2). The media recur-
rence-free survival time for patients with c-FLIP overex-
Expression pattern of c-FLIP in human HCC specimens and  corresponding noncancerous liver specimens with anti-c-FLIP  antibody Figure 1
Expression pattern of c-FLIP in human HCC speci-
mens and corresponding noncancerous liver speci-
mens with anti-c-FLIP antibody. A: Human HCC 
specimen with capsular formation; B: HCC specimen with 
extracapsular invasion; C: Hepatic cirrhosis specimen; D: 
Hemangioma specimen. (S-P, ×200).Journal of Experimental & Clinical Cancer Research 2009, 28:24 http://www.jeccr.com/content/28/1/24
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pression was 14 months compared with 22 months for
those without c-FLIP overexpression.
Expression of c-FLIP mRNA in different transfected cells
pSuper vector was used for the construction of the recom-
binant interfering vectors. DNA sequencing of the plas-
mids verified the successful construction of the c-FLIP
RNAi vectors. The three positive plasmids were termed as
pSuper-Si1, pSuper-Si2, and pSuper-Si3, containing the
distinct siRNA segment respectively. pSuper-Neg, without
the interfering segment, was used as the control.
We examined expression levels of c-FLIP mRNA in the
transfected cells with different recombinant vectors
(named 7721/pSuper-Si1, 7721/pSuper-Si2, 7721/pSu-
per-Si3 and 7721/pSuper-Neg, respectively), using a semi-
quantitative RT-PCR assay. The comparable amplification
efficiencies were validated by the uniformity of control β-
actin RT-PCR product yields. RT-PCR results showed that
the expression levels of c-FLIP mRNA were inhibited in
the transfected cells (Figure. 3A), but the expression levels
varied between these cells. c-FLIP mRNA expression in
7721/pSuper-Si1 cells was significantly lower than that in
the other two transfected cells.
Then we examined the effect of siRNA on the expression
of c-FLIP protein with Western Blot and immunocyto-
chemical staining. First, c-FLIP protein expression was
analyzed by Western blot analysis (Figure. 3B). pSuper-
Si1 obviously decreased the expression of c-FLIP protein.
The results supported the fact that si-526-siRNA inhibited
c-FLIP expression specifically. To further evaluate the
effect of siRNA, we studied the c-FLIP protein expression
by immunocytochemical staining. Immunocytochemical
analysis showed that the primary 7721 cells were strongly
immunostained with the anti-c-FLIP antibodies, com-
pared to 7721/pSuper-Si1.
Doxorubicin-induced apoptosis inhibited by siRNA
Cells were treated with doxorubicin for 0–8 days, and
then the growth curves were obtained. Cell proliferation
was inhibited obviously when c-FLIP expression was
knocked down by siRNA. Our data showed that si-526-
siRNA significantly decreased the growth rate of 7721
cells, with a >50% decrease after 3 days repeatedly in three
separate experiments (Figure. 4).
Then, the cells were assayed by the TUNEL method to
assess the drug-induced apoptosis. Positive TUNEL stain-
ing would be indicative of the DNA fragmentation that
was characteristic of apoptosis. Without c-FLIP RNAi, the
fewer 7721 cells were TUNEL positive. In contrast, in cells
transfected with the specific siRNA vector, pSuper-Si1, the
apoptosis induced by treatment with doxorubicin was sig-
nificantly elevated (Figure. 5).
Discussion
Tumor cells have developed different ways to escape
apoptosis induced by DR-triggering such as surface DR
down-regulation, loss or mutation. Other mechanisms
elaborated by tumor cells to develop cell death resistance
include aberrant expression of anti-apoptotic molecules
such as c-FLIP, Bcl-2, Bcl-xL, survivin and Livin. The cur-
rent belief holds that perturbations in apoptotic death reg-
ulation constitute a vital step in cancer evolution [17].
Each step in DR-mediated apoptosis is well regulated. c-
FLIP is a recently identified intracellular inhibitor of cas-
pase-8 activation that potently inhibits death signaling
mediated by all known death receptors, including Fas,
TNF-receptor (TNF-R), and TNF-related apoptosis-induc-
ing ligand receptors (TRAIL-Rs). Furthermore, c-FLIP over-
expression can activate nuclear factor (NF)-κB activation
Recurrence-free survival in relation to c-FLIP expression Figure 2
Recurrence-free survival in relation to c-FLIP expres-
sion. Increased c-FLIP immunoreactivity (c-FLIP overexpres-
sion) was associated with shortened survival (Kaplan-Meier 
curves).
Expression of c-FLIP c-FLIP mRNA and protein in the trans- fected cells Figure 3
Expression of c-FLIP mRNA and protein in the trans-
fected cells. A: c-FLIP mRNA. B: c-FLIP protein. (C: control 
cells transfected by pSuper-Neg; Si1: 7721 cells transfected 
by pSuper-Si1; Si2: 7721 cells transfected by pSuper-Si2; Si3: 
7721 cells transfected by pSuper-Si3;)Journal of Experimental & Clinical Cancer Research 2009, 28:24 http://www.jeccr.com/content/28/1/24
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induced by TNF-α or TRAIL. c-FLIP has a more central role
in the antiapoptotic NF-kB response than the TRAF/IAP
complex. On the other hand, c-FLIP expression is regu-
lated by NF-κB and phosphatidylinostiol-3 kinase (PI-3)/
Akt pathways. So, c-FLIP plays an important role in cell
survival not simply by inhibiting DR-mediated apoptosis
but also by regulating NF-κB activation in human HCCs
[10,18]. Moreover, c-FLIP has recently been shown to be
associated with the generation of positive signals for cell
proliferation by activation of the Erk pathway through
Raf-1 binding [19,20].
There is increasing evidence that in regard to its anti-apop-
totic functions, c-FLIP can be considered as a tumor-pro-
gression factor. At present, the role of c-FLIP, as an anti-
apoptotic protein involved in the regulation of the DR
extrinsic apoptotic pathway, remains unclear. Therefore,
the identification of the precise role of c-FLIP in cancer
cells represents an essential aim to further target and
restore deregulated death pathways.
c-FLIP is generally expressed in embryonic tissues, but is
not expressed in most normal adult tissues, whereas is
over-expressed in the majority of human cancers. It indi-
cates that c-FLIP may associate with the tumorigenesis and
progress of most human cancers. Published information
regarding the significance of c-FLIP over-expression in
human tumors has only recently begun to accumulate
[21-24].
Human HCCs show resistance to apoptosis mediated by
several death receptors. c-FLIP is constitutively expressed
in human HCC cell lines, and is expressed with a higher
positive rate in human HCC tissues than in noncancerous
liver tissues. In the present study, positive immunostain-
ing was detected for c-FLIP in 83.72% of human HCC
samples, but was absent from normal hepatic tissues. The
other authors' and our studies suggest that c-FLIP may
play an important role in human HCCs. For the patients
with c-FLIP overexpression, they may have a shorter recur-
rence-free survival time.
Now, RNAi, that can induce highly specific target gene
silencing in mammalian cells using siRNA, has been a
powerful tool in studying the cell function of any gene. c-
FLIP expression can be inhibited by RNA interference
using siRNAs, evidence from reduced levels of c-FLIP
mRNA and c-FLIP protein[25].
In this study, the c-FLIP-targeted siRNA vectors were
designed to specifically silence c-FLIP. Then, the plasmids
transcript containing c-FLIP-targeted siRNA and negative
siRNA were constructed and transfected into 7721 cells.
We found that there were significant differences between
7721/pSuper-Si1 and 7721/pSuper-Neg in c-FLIP expres-
sion at both mRNA and protein levels (Figure. 3A, Figure.
3B). The phenomenon that screened positive clone with
lower c-FLIP expression indicated that the c-FLIP-targeted
siRNA inhibited c-FLIP expression specifically.
Some studies reported that siRNA-mediated silencing of c-
FLIP induced spontaneous apoptosis in a panel of p53
wild-type, mutant, and null colorectal cancer cell lines
[11]. And the anti-apoptotic role of c-FLIP in regulating
TRAIL-mediated apoptosis in colon cancer cells was
clearly shown using siRNA methodology [26]. Further-
more, c-FLIP down-regulation sensitized colorectal cancer
Cell viability was accessed by cell counting Figure 4
Cell viability was accessed by cell counting. The study 
showed that 7721 cell viability was reduced by the transfet-
ion with recombinant iRNA vectors. pSuper-Si1 had more 
significant effect on the reduction of the cell viability.
Cells were assayed for apoptosis by the TUNEL method and  photographed by fluorescence microscopy at ×100 Figure 5
Cells were assayed for apoptosis by the TUNEL 
method and photographed by fluorescence micros-
copy at ×100. Green cells are positive for DNA fragmenta-
tion, consistent with apoptosis. A: 7721/pSuper-Neg; B: 
7721/pSuper-Si1.Journal of Experimental & Clinical Cancer Research 2009, 28:24 http://www.jeccr.com/content/28/1/24
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cells to chemotherapy [27]. And, specific silencing of c-
FLIPL was sufficient to sensitize MDA435 cells to doxoru-
bicin. Our study showed that c-FLIP gene silencing
enhanced doxorubicin-induced HCC cell apoptosis (Fig-
ure. 5). These results indicate that c-FLIP may be an
important regulator of chemotherapy-induced cell death
in human HCC cells.
Conclusion
The results of the present investigation demonstrated that
c-FLIP is frequently expressed in human HCCs, correlated
with Edmondson standard. The HCC patients with c-FLIP
overexpression may have a shorter recurrence-free survival
time. The specific silencing of c-FLIP can apparently
inhibit its expression on both protein and mRNA levels.
The inhibition of c-FLIP expression can down-regulate
HCC cell viability and up-regulate drug-induced cell
apoptosis. Our data suggest that targeting c-FLIP in con-
junction with anticancer therapies may have therapeutic
potential by enhancing HCC cell death.
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